Jobs
-
Theravance Biopharma has announced the initiation of a Phase 4 study of Yupelri revefenacin inhalation solution, which was approved by the FDA in 2018 for the treatment of COPD. The PIFR-2 study, which is expected to… Read more . . .
-
RxPack, a new device company formed from a joint venture between Lindal and Coster in 2021, has announced the appointment of inhaler development specialist Alberto Colombo as Head of R&D and Customer Technical Support. Colombo… Read more . . .
-
According to Quantum Leap Healthcare Collaborative (QLHC), a sponsor of the I-SPY COVID trial, interim analysis of data from a study of Genentech’s Pulmozyme dornase alfa inhalation solution for the treatment of severe COVID-19 found that… Read more . . .
-
DPI developer PureIMS has announced the appointment of Jaap Wieling as Chief Executive Officer (CEO), succeeding Bram Van Dijck. According to his LinkedIn page, Wieling founded or co-founded several biopharm companies, including Bioralix, BiosanaPharma, and… Read more . . .
-
Covis Pharma Canada announced that it has signed a 7-year promotion and distribution agreement with Novartis Pharmaceuticals Canada for exclusive rights to Seebri Breezhaler glycopyrronium DPI and Ultibro Breezhaler indacaterol / glycopyrronium for the treatment of COPD in… Read more . . .
-
Pfizer is paying Biohaven Pharmaceutical a total of $500 million upfront plus up to $740 million in potential milestone payments for the rights to market Biohaven’s rimegepant (Nurtec ODT) and zavegepant (BHV-3500) outside of the… Read more . . .
-
MannKind Corporation said that it has purchased an additional convertible note issued by Thirona Bio, and MannKind CEO Michael Castagna has joined the Thirona board of directors, extending a June 2021 deal between the two companies for… Read more . . .
-
Intranasal vaccine developer Intravacc and Leiden University Medical Center (LUMC) have announced a planned Phase 1/2 trial of LUMC’s Nanovac intranasal vaccine against coronaviruses, including SARS, MERS, and SARS-CoV-2. The trial is expected to begin… Read more . . .
-
Israeli biopharm SpliSense has announced that both the FDA and the EMA have granted orphan drug designation to the company’s SPL84-23-1 inhaled antisense oligonucleotide (ASO) for the treatment of cystic fibrosis associated with the 3849+10… Read more . . .
-
According to Iliad Biotechnologies, the FDA has granted Fast Track designation to Iliad’s BPZE1 live attenuated intranasal vaccine against pertussis (whooping cough), which is in Phase 2 development as a booster vaccine to prevent both… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA